Search bioRxiv⌕ Search

Biology subjects

Mansky, R. H.

Publications and source records attributed to Mansky, R. H..

2 recordsLinked to original sources

Enhanced Hippocampal Spare Capacity in Q175DN Mice Despite Elevated mHTT Aggregation

BackgroundHuntingtons disease (HD) is a neurodegenerative disease resulting in devastating motor, cognitive, and psychiatric deficits. The striatum is a brain region that controls movement and some forms of cognition and is most significantly impacted in HD. However, despite well-documented deficits in learning and memory in HD, knowledge of the potential implication of other brain regions such as the hippocampus remains limited. ObjectiveHere, we study the comparative impact of enhanced mHTT aggregation and neuropathology in the striatum and hippocampus of two HD mouse models. MethodsWe utilized the zQ175 as a control HD mouse model and the Q175DN mice lacking the PGK-Neomycin cassette generated in house. We performed a comparative characterization of the neuropathology between zQ175 and Q175DN mice in the striatum and the hippocampus by assessing HTT aggregation, neuronal and glial pathology, chaperone expression, and synaptic density. ResultsWe showed that Q175DN mice presented enhanced mHTT aggregation in both striatum and hippocampus compared to zQ175. Striatal neurons showed a greater susceptibility to enhanced accumulation of mHTT than hippocampal neurons in Q175DN despite high levels of mHTT in both regions. Contrary to the pathology seen in the striatum, Q175DN hippocampus presented enhanced spare capacity showing increased synaptic density, decreased Iba1+ microglia density and enhanced HSF1 levels in specific subregions of the hippocampus compared to zQ175. ConclusionsQ175DN mice are a valuable tool to understand the fundamental susceptibility differences to mHTT toxicity between striatal neurons and other neuronal subtypes. Furthermore, our findings also suggest that cognitive deficits observed in HD animals might arise from either striatum dysfunction or other regions involved in cognitive processes but not from hippocampal degeneration.

neuroscience↗

Identification of CK2α' selective inhibitors by the screening of an allosteric-kinase-inhibitor-like compound library

Protein Kinase CK2 is a holoenzyme composed of two regulatory subunits (CK2{beta}) and two catalytic subunits (CK2 and CK2). CK2 controls several cellular processes including proliferation, inflammation, and cell death. However, CK2 and CK2 possess different expression patterns and substrates and therefore impact each of these processes differently. Elevated CK2 participates in the development of cancer, while increased CK2 has been associated with neurodegeneration, especially Huntingtons disease (HD). HD is a fatal disease for which no effective therapies are available. Genetic deletion of CK2 in HD mouse models has ameliorated neurodegeneration. Therefore, pharmacological inhibition of CK2 presents a promising therapeutic strategy for treating HD. However, current CK2 inhibitors are unable to discriminate between CK2 and CK2 due to their high structural homology, especially in the targeted ATP binding site. Using computational analyses, we found a potential Type IV ("D" pocket) allosteric site on CK2 that contained different residues than CK2 and was distal from the ATP binding pocket featured in both kinases. With this potential allosteric site in mind, we screened a commercial library containing [~]29,000 allosteric-kinase-inhibitor-like compounds using a CK2 activity-dependent ADP-GloTM Kinase assay. Obtained hits were counter-screened against CK2 revealing two CK2 selective compounds. These two compounds might serve as the basis for further medicinal chemistry optimization for the potential treatment of HD.

biochemistry↗